CIK 0001778016 · Non-accelerated filer
NovaBridge Biosciences
Sign in to watch- Ticker
- NBP
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- Cayman Islands
- Entity type
- other
- Phone
- (301) 670 2800
- Business address
- SUITE 400, 2440 RESEARCH BLVD, ROCKVILLE, MD, 20850
- Former names
- I-Mab
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $88,325
- in 3 filings
Net −$88,325. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-10-15 | Woo Ian Ying Director | Option exercise | +13,271 | 13,271 | ||
| 2026-10-15 | Woo Ian Ying Director | Option exercise · Restricted Share Units | −5,770 | 11,540 | ||
| 2026-09-18 | Dennis Phillip Andrew Chief Medical Officer | Sale | −8,209 | $0.71 | $6K | 173,427 |
| 2026-09-17 | Dennis Phillip Andrew Chief Medical Officer | Option exercise | +23,695 | 181,636 | ||
| 2026-09-17 | Dennis Phillip Andrew Chief Medical Officer | Option exercise · Restricted Share Units | −10,302 | 72,120 | ||
| 2026-09-09 | Cao Sean Wuxiong Chief Bus. Development Officer | Sale | −107,978 | $0.74 | $80K | 266,467 |
| 2026-09-03 | Cao Sean Wuxiong Chief Bus. Development Officer | Option exercise | +235,136 | 270,209 | ||
| 2026-09-03 | Cao Sean Wuxiong Chief Bus. Development Officer | Option exercise | +104,236 | 374,445 | ||
| 2026-09-03 | Cao Sean Wuxiong Chief Bus. Development Officer | Option exercise · Restricted Share Units | −102,233 | 306,700 | ||
| 2026-09-03 | Cao Sean Wuxiong Chief Bus. Development Officer | Option exercise · Restricted Share Units | −45,320 | 135,960 | ||
| 2026-08-31 | Xu Cong Claire EVP, Clinical Development | Sale | −3,282 | $0.79 | $3K | 304,201 |
| 2026-08-30 | Xu Cong Claire EVP, Clinical Development | Option exercise | +9,382 | 307,483 | ||
| 2026-08-30 | Xu Cong Claire EVP, Clinical Development | Option exercise · Restricted Share Units | −4,079 | 28,558 | ||
| 2026-08-22 | Lenz Robert A. Director | Option exercise | +17,218 | 17,218 | ||
| 2026-08-22 | Lenz Robert A. Director | Option exercise · Restricted Share Units | −7,486 | 14,974 | ||
| 2026-07-08 | Hagler Mark Arnold Chief Commercial Officer | Grant or award · 2025 Employee Share Option (right to buy) | +949,050 | 949,050 | ||
| 2026-07-08 | Lin Liwei Lorraine General Counsel | Grant or award · 2025 Employee Share Option (right to buy) | +254,780 | 254,780 | ||
| 2026-07-06 | Gupta Srishti Chief Executive Officer | Grant or award · 2025 Employee Share Option (right to buy) | +3,000,000 | 3,000,000 | ||
| 2026-07-06 | Xu Cong Claire SVP, Clinical Development | Sale | −4,485 | $0.89 | $4K | 298,101 |
| 2026-07-04 | Xu Cong Claire SVP, Clinical Development | Option exercise | +12,432 | 302,586 |
Page 1 of 2 · 35 trades